Arcus Biosciences, Inc.
RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimabā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$19.31
Price-1.30%
-$0.26
1Y
Price
Market Cap
$2.085b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+2.5%
EBITDA Margin-5.0%
Net Profit Margin-83.1%
Free Cash Flow MarginRevenue
$262m
+1.6%
1y CAGR+42.2%
3y CAGR+13.9%
5y CAGREarnings
-$306m
-8.1%
1y CAGR-5.1%
3y CAGR-154.8%
5y CAGREPS
-$3.18
-1.3%
1y CAGR+3.7%
3y CAGR-152.8%
5y CAGRBook Value
$549m
$1.075b
Assets$526m
Liabilities$109m
DebtDebt to Assets
10.1%
-0.4x
Debt to EBITDAFree Cash Flow
-$342m
-94.3%
1y CAGR-75.0%
3y CAGR+6.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company